A topical combination product containing a potent corticosteroid (Betamethasone) and an astringent, mild antiseptic (Zinc Sulfate). Betamethasone provides potent anti-inflammatory, anti-pruritic, and vasoconstrictive effects, while Zinc Sulfate offers astringent, soothing, and mild antiseptic properties, aiding in wound healing and reducing exudation. This combination is particularly effective for inflammatory dermatoses with exudation or secondary infection risk.
Adult: Apply a thin film to the affected area 1-2 times daily. The frequency should be reduced to once daily or on alternate days as the condition improves. Total duration should not exceed 2-4 weeks continuously without medical review.
Note: Wash and dry the affected area gently. Apply a thin layer and rub in lightly until it disappears. Do not bandage or cover unless directed by a physician. Wash hands after application unless hands are the treatment area. Avoid contact with eyes, mouth, nose, and mucous membranes.
Betamethasone binds to cytoplasmic glucocorticoid receptors, forming a complex that translocates to the nucleus. It modulates gene transcription, leading to the synthesis of anti-inflammatory proteins (lipocortin) and inhibition of pro-inflammatory mediators (cytokines, chemokines, prostaglandins, leukotrienes). It also causes vasoconstriction, reducing erythema and edema. Zinc Sulfate acts as an astringent, precipitating proteins to form a protective layer, reducing exudation, and providing a mild antiseptic effect against bacteria like *Staphylococcus aureus*.
Pregnancy: Category C (US FDA). Topical corticosteroids can be absorbed in small amounts. Use only if the potential benefit justifies the potential risk to the fetus. Avoid large amounts, prolonged use, or use under occlusion. Do not use on pregnant breasts if preparing to nurse.
Driving: No effect on driving ability.
| Other Topical Corticosteroids | Additive risk of local and systemic side effects. | Major |
| Topical Immunosuppressants (e.g., Tacrolimus, Pimecrolimus) | May increase risk of infection. Sequential use should be monitored. | Moderate |
| Live Attenuated Vaccines | Systemic immunosuppression may impair vaccine efficacy and increase risk of infection. | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | May increase systemic levels of betamethasone if absorbed, increasing side effect risk. | Moderate |
Same composition (Betamethasone (0.05% w/w) + Zinc Sulfate (0.5% w/w)), different brands: